

VIVALDIS V
Animal Health

PetSmile

EDITION-160



NICLOSAMIDE PRODRUG SHOWS BREAKTHROUGH POTENTIAL IN OSTEOSARCOMA

A novel niclosamide-based prodrug (mNSPT) is emerging as a promising advancement in the treatment of osteosarcoma—an aggressive bone cancer with limited therapeutic progress. Originally used as an antiparasitic, niclosamide has well-known anticancer properties, but its clinical use has been restricted due to poor bioavailability. This challenge has now been addressed through a nanoparticle-based intravenous formulation, enabling improved drug delivery and effective therapeutic levels.


In a recent study involving dogs with naturally occurring osteosarcoma, this approach demonstrated encouraging results—delaying metastasis (~510 days) and extending median survival (~632 days), with some cases exceeding 4 years. The treatment was generally well tolerated, with manageable infusion-related effects such as mild fever and transient liver enzyme elevation.

While these findings are still preliminary, they highlight the potential of drug repurposing combined with advanced delivery systems to redefine cancer therapy. This could pave the way for future breakthroughs not only in veterinary oncology but also in human medicine.



OCOXIN

150 ml



TOCERAPET

10, 15, 50 mg tablets

10 x 1 x 4 tablets

UNUSUAL KIDNEY FATS MAY BE THE MISSING LINK IN CKD

A recent discovery by researchers at the University of Nottingham is reshaping our understanding of chronic kidney disease (CKD), particularly in cats. The study found that cats uniquely accumulate rare, modified triglycerides in their kidneys from an early age—lipids with distinct chemical structures that differ from typical fats. This abnormal buildup is believed to act as an early indicator of cellular stress, potentially leading to progressive kidney damage over time. Interestingly, these lipid patterns are not seen in dogs and are only rarely observed in wildcats, suggesting a species-specific metabolic trait that may explain the high prevalence of CKD in domestic cats. This breakthrough opens new possibilities for early diagnosis, targeted nutritional interventions, and innovative therapies aimed at slowing disease progression. While further research is needed, it marks a significant step toward understanding the root cause of CKD and improving long-term kidney health in veterinary medicine.

Reno-nex
20 g powder




BEZAFIBRATE FOR MANAGING HYPERTRIGLYCERIDEMIA IN DOGS

A recent study highlights bezafibrate as a promising long-term therapy for managing hypertriglyceridemia in dogs, a metabolic condition often associated with disorders like diabetes, hypothyroidism, and hyperadrenocorticism. Traditionally managed through dietary fat restriction and omega-3 supplementation, more severe cases have limited pharmacological options. The study demonstrated that bezafibrate can reduce triglyceride levels by up to 85%, showing consistent effectiveness in both primary and secondary cases while maintaining a favorable safety profile over extended use. Effective control of triglyceride levels is crucial, as untreated hypertriglyceridemia can lead to serious complications such as pancreatitis, insulin resistance, gallbladder disease, and neurological issues. These findings position bezafibrate as a valuable addition to canine metabolic therapy, offering improved disease management and better long-term outcomes.



EFA Pet

3 g x 30 sachets



VIVALDIS EVENTS

Vivaldis Launches Thrive Shared Journey campaign

The Thrive Shared Journey campaign reflects Bark Out Loud by Vivaldis Animal Health's continued commitment to advancing companion animal wellbeing through thoughtful innovation and purposeful storytelling. Fronted by Huma Qureshi, the campaign captures the evolving mindset of today's pet parents, where care extends beyond basic nutrition to a more holistic, emotionally connected approach.

At its core, Thrive is positioned as a science-backed, high-quality nutrition range designed to support pets at every stage of life. The campaign brings this to life by highlighting the shared journey of growth, resilience, and wellbeing between pets and their parents. By combining product integrity with culturally relevant narratives, we reinforce its vision of enabling both pets and pet parents to truly thrive together.

THRIVE DAILY BARK PROUDLY



VIVALDIS EVENTS

A meaningful journey across two impactful platforms

At PetFed Mumbai, Bark Out Loud connected with a vibrant community of pet parents and their furry companions—showcasing thoughtfully crafted products and creating engaging, interactive experiences that celebrate the joy of pet parenting.

Simultaneously, at the 11th Indian Vetopia 2026, Vivaldis Animal Health engaged with 400+ veterinary professionals, contributing to insightful discussions on the growing importance of supportive therapies in veterinary oncology.

Together, these experiences highlight our continued commitment to enhancing pet wellness while collaborating with the veterinary community to improve treatment outcomes.



Mumbai



Guwahati



VIVALDIS EVENTS

Driving impact through care, collaboration, and commitment

Vivaldis Animal Health was honored to sponsor the **Veterinary Cancer Conclave 2026** at Goa Marriott—bringing together veterinary surgeons, pathologists, and human oncologists for a hands-on, multidisciplinary learning experience. From diagnostics to real-world treatment protocols and neuro-oncology, the conclave reinforced the importance of collaboration in advancing cancer care and improving outcomes for pets.



Goa



Jaipur, Delhi, Bangalore, Pune & Mumbai

Extending this commitment beyond clinics, our CSR initiative **Har Dog Karega Thrive** reached over 3,000 community dogs across Jaipur, Delhi, Bangalore, Pune, and Mumbai. In partnership with NGOs, the distribution of Thrive dog food & Atopivet collars helped enhance health, comfort, and quality of life—ensuring care reaches every dog, everywhere.

